Celcuity Inc.
CELCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCelcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. Valued at $4.68B, CELC is a mid-cap name in its sector. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Market Cap
$4.68B
Beta
0.20
P/E (TTM)
—
P/E (Fwd)
-1196.25
EPS (TTM)
$-4.30
EPS (Fwd)
$-0.08
ROE
-1433.7%
ROA
-25.8%
Cash
$754.0M
Total Debt
$754.4M
Free CF
-$72.0M
52W Change
57.5%
Annual Financials
Cash vs Debt
Where CELC stands vs its 150-day and 200-day moving averages
As of the August 7, 2026 close, CELC finished 14.63% below its 150-day moving average ($109.23) and 10.81% below its 200-day moving average ($104.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CELC overbought or oversold?
At the August 7, 2026 close, CELC's RSI(14) was 59.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $754.0M in cash, though total debt stands at $754.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$72.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -1433.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
CELC's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Celcuity Inc. and its sector.